About the Study

Leukemia (B-cell acute lymphoblastic leukemia (B-ALL), Mixed Phenotype Acute Leukemia (MPAL), and B-Lly: A clinical trial adding study treatment to standard treatment

Those who are ages 1 to 25 and diagnosed with High Risk B-ALL, MPAL, or B-LLy are eligible to join this study. We would like to collect information about participants' leukemia and the effects of the first two phases of treatment, called Induction and Consolidation. For those diagnosed with High Risk B-ALL, we would like to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves outcomes. For those diagnosed with MPAL, we would like to determine the outcomes to treatment using High Risk B-ALL therapy. For those diagnosed with B-LLy, we would like to determine the outcomes to treatment using High Risk B-ALL therapy.

Interested in learning more?

Full Study Name: AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy